[go: up one dir, main page]

PE20071100A1 - Derivados de azepinoindol como agentes farmaceuticos - Google Patents

Derivados de azepinoindol como agentes farmaceuticos

Info

Publication number
PE20071100A1
PE20071100A1 PE2006001614A PE2006001614A PE20071100A1 PE 20071100 A1 PE20071100 A1 PE 20071100A1 PE 2006001614 A PE2006001614 A PE 2006001614A PE 2006001614 A PE2006001614 A PE 2006001614A PE 20071100 A1 PE20071100 A1 PE 20071100A1
Authority
PE
Peru
Prior art keywords
substituted
alkyl
tetrahidroazepino
indol
rental
Prior art date
Application number
PE2006001614A
Other languages
English (en)
Inventor
Taegon Baik
Chris A Buhr
Brett B Busch
Diva Sze-Ming Chan
Brenton T Flatt
Xiao Hui Gu
Vasu Jammalamadaka
Richard George Khoury
Katherine Lara
Sunghoon Ma
Richard Martin
Raju Mohan
John M Nuss
Jason Jevious Park
Longcheng Wang
Tie Ling Wang
Wei Xu
Bryan K S Yeung
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of PE20071100A1 publication Critical patent/PE20071100A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

SE REFIERE A UN COMPUESTO DE FORMULA I, DODNE R1 ES -C(J)R11, -C(J)OR11, -C(J)N(R10)(R11); J ES UN ENLACE DIRECTO, NR10; n ES 0-4; R3 ES H, C(O)R9, CON(R11)(R12); R6 Y R7 SON CADA UNO ALQUILO SUSTITUIDO O NO, CICLOALQUILO SUSTITUIDO O NO, CICLOALQUILALQUILO SUSTITUIDO O NO; R8 ES OH, ALQUILO SUSTITUIDO O NO, HALO, HALOALCOXI, HALOALQUILO, ENTRE OTROS; R9 ES ALQUILO SUSTITUIDO O NO, ARALQUILO SUSTITUIDO O NO, ALQUINILO SUSTITUIDO O NO, ENTRE OTROS; R10 ES H, ALQUILO SUSTITUIDO O NO, HETEROCICLILO SUSTITUIDO O NO, ENTRE OTROS; R11 ES H, ALQUILO SUSTITUIDO O NO, ALQUINILO SUSITUIDO O NO, ENTRE OTROS; R12 ES H, ALQUILO SUSTITUIDO O NO, ALQUENILO SUSTITUIDO O NO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: 1-METILETIL 1,1-DIMETIL-3-{[(1S,4S)-5-METIL-2,5-DIAZABICICLO[2.2.1]HEPT-2-IL]CARBONIL}-1,2,3,6-TETRAHIDROAZEPINO[4,5-b]INDOL-5-CARBOXILATO; 1-METILETIL 1,1-DIMETIL-3-({4-[(1-METILPIPERIDIN-4-IL)METIL]PIPERAZIN-1-IL}CARBONIL)-1,2,3,6-TETRAHIDROAZEPINO[4,5-b]INDOL-5-CARBOXILATO; ENTRE OTROS. DICHOS COMPUESTOS SON MODULADORES DE LOS RECEPTORES NUCLEARES ESPECIALMENTE FARNESOIDE X UTILES EN EL TRATAMIENTO ATEROSCLEROSIS Y RELACIONADOS
PE2006001614A 2005-12-15 2006-12-15 Derivados de azepinoindol como agentes farmaceuticos PE20071100A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75063405P 2005-12-15 2005-12-15
US75067905P 2005-12-15 2005-12-15

Publications (1)

Publication Number Publication Date
PE20071100A1 true PE20071100A1 (es) 2007-12-21

Family

ID=37946206

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2006001614A PE20071100A1 (es) 2005-12-15 2006-12-15 Derivados de azepinoindol como agentes farmaceuticos

Country Status (13)

Country Link
US (1) US20090203577A1 (es)
EP (1) EP1963331A1 (es)
JP (2) JP5420908B2 (es)
AR (1) AR058781A1 (es)
AU (1) AU2006325815B2 (es)
BR (1) BRPI0620156A2 (es)
CA (1) CA2633243C (es)
EC (1) ECSP088623A (es)
IL (1) IL191907A0 (es)
PE (1) PE20071100A1 (es)
RU (1) RU2008128823A (es)
TW (1) TW200745124A (es)
WO (1) WO2007070796A1 (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1648408A4 (en) * 2003-07-23 2006-11-29 Exelixis Inc AZEPINE DERIVATIVES AS PHARMACEUTICAL AGENTS
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
CA2727055C (en) 2008-01-11 2016-12-20 Albany Molecular Research, Inc. (1-azinone) -substituted pyridoindoles as mch antagonists
RU2532545C2 (ru) 2008-03-27 2014-11-10 Грюненталь Гмбх Замещенные производные 4-аминоциклогексана
PE20091822A1 (es) * 2008-03-27 2009-12-10 Gruenenthal Chemie Hidroximetilciclohexilaminas
EP2110374A1 (en) 2008-04-18 2009-10-21 Merck Sante Benzofurane, benzothiophene, benzothiazol derivatives as FXR modulators
WO2010036362A1 (en) * 2008-09-26 2010-04-01 Wyeth 1,2,3,6-tetrahydroazepino[4,5-b]indole-5-carboxylate nuclear receptor inhibitors
AR074760A1 (es) * 2008-12-18 2011-02-09 Metabolex Inc Agonistas del receptor gpr120 y usos de los mismos en medicamentos para el tratamiento de diabetes y el sindrome metabolico.
WO2011003012A1 (en) 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Azinone-substituted azapolycycle mch-1 antagonists, methods of making, and use thereof
EP2448585B1 (en) 2009-07-01 2014-01-01 Albany Molecular Research, Inc. Azinone-substituted azepino[b]indole and pyrido-pyrrolo-azepine mch-1 antagonists, methods of making, and use thereof
WO2011003021A1 (en) 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Azinone-substituted azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine mch-1 antagonists, methods of making, and use thereof
WO2011003007A1 (en) 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine mch-1 antagonists, methods of making, and use thereof
TW201139370A (en) 2009-12-23 2011-11-16 Lundbeck & Co As H Processes for the manufacture of a pharmaceutically active agent
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
ITRM20100329A1 (it) * 2010-06-15 2011-12-16 Franco Baldelli Modulazione del recettore nucleare per i farnesoidi (fxr) con molecole agoniste per la prevenzione e trattamento di fenomeni aterosclerotici indotti da somministrazione di inibitori delle proteasi
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8993765B2 (en) 2010-12-21 2015-03-31 Albany Molecular Research, Inc. Tetrahydro-azacarboline MCH-1 antagonists, methods of making, and uses thereof
US8697700B2 (en) 2010-12-21 2014-04-15 Albany Molecular Research, Inc. Piperazinone-substituted tetrahydro-carboline MCH-1 antagonists, methods of making, and uses thereof
EP2683700B1 (de) 2011-03-08 2015-02-18 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120053A1 (de) 2011-03-08 2012-09-13 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8710050B2 (en) 2011-03-08 2014-04-29 Sanofi Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120052A1 (de) 2011-03-08 2012-09-13 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2545964A1 (en) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
EP3116878A4 (en) * 2014-03-13 2018-02-14 Salk Institute for Biological Studies Fxr agonists and methods for making and using
US10077268B2 (en) 2014-03-13 2018-09-18 Salk Institute For Biological Studies FXR agonists and methods for making and using
US10301268B2 (en) 2014-03-13 2019-05-28 The Salk Institute For Biological Studies Analogs of fexaramine and methods of making and using
RU2741387C2 (ru) 2014-12-22 2021-01-25 Акарна Терапьютикс, Лтд. Конденсированные бициклические соединения для лечения заболевания
MX370897B (es) * 2015-03-26 2020-01-09 Akarna Therapeutics Ltd Compuestos bicíclicos fusionados para el tratamiento de enfermedades,
WO2017078928A1 (en) * 2015-11-06 2017-05-11 Salk Institute For Biological Studies Fxr agonists and methods for making and using
WO2017143134A1 (en) * 2016-02-19 2017-08-24 Alios Biopharma, Inc. Fxr modulators and methods of their use
KR102269305B1 (ko) 2016-06-13 2021-06-25 길리애드 사이언시즈, 인코포레이티드 Fxr (nr1h4) 조정 화합물
CA2968836C (en) 2016-06-13 2025-09-02 Gilead Sciences Inc Fxr (nr1h4) modulating compounds
PL3600309T3 (pl) 2017-03-28 2022-11-07 Gilead Sciences, Inc. Skojarzenia terapeutyczne do leczenia chorób wątroby
CA3059869C (en) 2017-04-12 2022-01-04 Il Dong Pharmaceutical Co., Ltd. Isoxazole derivatives as nuclear receptor agonists and uses thereof
HRP20240265T1 (hr) 2019-01-15 2024-05-10 Gilead Sciences, Inc. Spoj izoksazola kao fxr agonist i farmaceutski pripravci koji ga sadrže
CN118388473A (zh) 2019-02-19 2024-07-26 吉利德科学公司 Fxr激动剂的固体形式

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2663935A1 (fr) * 1990-06-27 1992-01-03 Adir Nouveaux 1,2,3,4,5,6-hexahydroazepino [4,5-b] indoles et 1,2,3,4-tetrahydrobethacarbolines, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent.
MY122278A (en) * 1999-07-19 2006-04-29 Upjohn Co 1,2,3,4,5,6-hexahydroazepino[4,5-b]indoles containing arylsulfones at the 9-position
TWI329111B (en) * 2002-05-24 2010-08-21 X Ceptor Therapeutics Inc Azepinoindole and pyridoindole derivatives as pharmaceutical agents
US7595311B2 (en) * 2002-05-24 2009-09-29 Exelixis, Inc. Azepinoindole derivatives as pharmaceutical agents
EP1648408A4 (en) * 2003-07-23 2006-11-29 Exelixis Inc AZEPINE DERIVATIVES AS PHARMACEUTICAL AGENTS

Also Published As

Publication number Publication date
WO2007070796A1 (en) 2007-06-21
AU2006325815A1 (en) 2007-06-21
RU2008128823A (ru) 2010-01-20
TW200745124A (en) 2007-12-16
CA2633243C (en) 2014-05-27
ECSP088623A (es) 2008-08-29
AR058781A1 (es) 2008-02-20
IL191907A0 (en) 2008-12-29
BRPI0620156A2 (pt) 2011-12-20
US20090203577A1 (en) 2009-08-13
JP2009519964A (ja) 2009-05-21
CA2633243A1 (en) 2007-06-21
JP5420908B2 (ja) 2014-02-19
EP1963331A1 (en) 2008-09-03
AU2006325815B2 (en) 2012-07-05
JP2014028829A (ja) 2014-02-13

Similar Documents

Publication Publication Date Title
PE20071100A1 (es) Derivados de azepinoindol como agentes farmaceuticos
CO6270320A2 (es) Derivados de piperidina utiles como antagonistas del receptor orexina
CO5590957A2 (es) Amino-1,3,5-triazinas sustituidas en n con radicales biciclicos quirales, procedimiento para su preparacion, composiciones de las mismas y su uso como herbicidas y reguladores del crecimiento de las plantas
PE20060555A1 (es) Derivados de pirrol-oxindol como moduladores del receptor de progesterona
PE20080677A1 (es) Inhibidores de pirrolotriazina cinaza
PE20211911A1 (es) Compuestos heterociclicos como inmunomoduladores
AR066144A1 (es) Derivados de aril pirrolidinas utiles como insecticidas y/o acaricidas y composiciones insecticidas que los contienen.
PE20010544A1 (es) Derivados de mutilina utiles como agentes antibacterianos
PE20090816A1 (es) Derivados de pirrolopirimidinona como agentes ligandos de los receptores p2x3
AR056317A1 (es) Compuestos de oxindol y composicion farmaceutica
PE20060383A1 (es) Nuevos derivados amino de urea ciclicos como inhibidores de quinasa
PE20090276A1 (es) Compuestos derivados de imidazoquinolina como moduladores de tlr7
PE20080839A1 (es) Determinadas amidas sustituidas, metodo de elaboracion y metodo de uso de las mismas
PE20051141A1 (es) Inhibidores de la polimerasa viral
AR047076A1 (es) Compuestos de pirrolotriazina como inhibidores de tirosina quinasas, composiciones farmaceuticas
AR044795A1 (es) Derivados de pirido [2,1-a] isoquinolina como inhibidores de la dpp-iv
PE20091381A1 (es) Inhibidores del virus de la hepatitis c
PE20090151A1 (es) Derivados de pirimidinona y metodos para su uso
AR072576A1 (es) Metodo para la represion de malezas en un cesped
AR072952A1 (es) Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso
AR076838A1 (es) Sulfonamidas nematocidas
PE20120693A1 (es) Compuestos heterociclos como moduladores de la piruvato cinasa m2 (pkm2)
PE20091573A1 (es) Derivados heterociclicos de urea como inhibidores de adn girasa y/o topoisomerasa
AR042943A1 (es) Insecticidas de ciano antranilamida
AR037907A1 (es) Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6

Legal Events

Date Code Title Description
FX Voluntary withdrawal